AS

ANDREW SPERLING

INTRA-CELLULAR THERAPIES, INC. · New York, NY · registered since 2024
Registered · LDAActive

At a glance

Registered since
2024
Senate LDA system
Clients
1
last 3 years
Filings
4
3 agencies contacted
Activity
filings by quarter
Works on

Background

Career
New York, NY
2024 - present

Specific issues

HR 3938: Build it in America Act - Provisions regarding research and development tax credit amortization. S. 866: American Innovation and Jobs Act - Provisions regarding research and development tax credit amortization.
Taxation/Internal Revenue Code · 2024 Q4
P.L. 117-169: Legislation not yet introduced; Negotiation regarding IRA Maximum Fair Price (MFP) and small manufacturer exception. H.R. 7174: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program - Provisions regarding reforms to the Inflation Reduction Act (IRA) MFP negotiation process.
Medicare/Medicaid · 2024 Q4
S. 1339: Pharmacy Benefit Manager Reform Act - Provisions regarding regulation of pharmacy benefit managers. S. 2973: Modernizing and Ensuring PBM Accountability Act - Provisions regarding regulation of pharmacy benefit managers.
Health Issues · 2024 Q4
HR 2630/S. 652: Safe Step Act - Provisions regarding protocol for step therapy in pharmacy benefits. S. 1339: Pharmacy Benefit Manager Reform Act - Provisions regarding regulation of pharmacy benefit managers. S. 2973: Modernizing and Ensuring PBM Accountability Act - Provisions regarding regulation of pharmacy benefit managers.
Health Issues · 2024 Q3
HR 3938: Build it in America Act - Provisions regarding research and development tax amortization. S. 866: American Innovation and Jobs Act - Provisions regarding research and development tax amortization.
Taxation/Internal Revenue Code · 2024 Q3
P.L. 117-169: Legislation not yet introduced; Negotiation regarding IRA Maximum Fair Price (MFP) and small manufacturer exception. H.R. 7174: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program - Provisions regarding reforms to the Inflation Reduction Act (IRA) MFP negotiation process. Part D 6 protected classes policy. Medicaid Drug Rebate Program Rule - Provisions regarding "stacking" of rebates and discounts.
Medicare/Medicaid · 2024 Q3

Clients

$██,███ / qtrUnlock

Filing history

2024 Q4
INTRA-CELLULAR THERAPIES, INC.
Q4lda.gov →
2024 Q3
INTRA-CELLULAR THERAPIES, INC.
Q3lda.gov →
2024 Q2
INTRA-CELLULAR THERAPIES, INC.
Q2lda.gov →
2024 Q1
INTRA-CELLULAR THERAPIES, INC.
Q1lda.gov →
Showing recent filings · full history on lda.gov